Professor Mingzhao Xing

      

Professor Mingzhao Xing

Editor-in-Chief: Dr. Michael Mingzhao Xing


Mingzhao Xing, M.D., PhD., is a Professor of Medicine, Oncology and Cellular and Molecular Medicine, Co-Director of the Thyroid Tumor Center, and Chief of the Laboratory for Cellular and Molecular Thyroid Research at the Johns Hopkins University School of Medicine.  Following his initial medical training at the Second Military Medical University in Shanghai, China, he obtained a PhD. degree in Physiology and Biophysics at Case Western Reserve University in Cleveland.  After completing an internal medicine residency at the Greater Baltimore Medical Center and a clinical fellowship in Endocrinology and Metabolism of the Johns Hopkins University School of Medicine, he joined the faculty of Endocrinology and Metabolism of the Johns Hopkins Hospital.  Dr. Xing has served on a number of national and international professional committees and panels, including, for example, National Institute of Health study sections, American Thyroid Association’s committees, and several international research grant review panels.  He serves also as an editorial board member or scientific editor for a number of endocrine journals, such as the Journal of Clinical Endocrinology and Metabolism, the Journal of Thyroid Research, Endocrine-Related Cancer, and Thyroid (ATA’s journal).  Dr. Xing practices clinical endocrinology as a subspecialty consultant, teaches at Johns Hopkins Hospital, while also conducting laboratory research as a physician-scientist.  His special clinical and research interest is in thyroid diseases, particularly thyroid tumors.  Supported by the American Cancer Society and NIH R0-1 grants, his laboratory has been studying molecular, genetic and epigenetic mechanisms of thyroid cancer and their clinical translations, particularly in relation to the MAP kinase and PI3K/Akt pathways.  He has published more than 80 scientific papers and is co-holder of a patent on the initial discovery and clinical characterization of BRAF mutation in thyroid cancer. Among his professional recognitions and awards are the US FAMRI Clinical Innovator Award, Maryland Innovator Award, American Cancer Society RSG Award, and “America’s Top Physician” recognition.